Technical Analysis for INCY - Incyte Corporation

Grade Last Price % Change Price Change
grade A 78.59 1.97% 1.52
INCY closed up 1.97 percent on Friday, April 3, 2020, on 1.18 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical INCY trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 50 DMA Bullish 1.97%
Stochastic Reached Overbought Strength 1.97%
Overbought Stochastic Strength 1.97%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies, as well as baricitinib, a JAK inhibitor, which is Phase III trial for rheumatoid srthritis, Phase IIb trial for psoriasis, and Phase II trial for diabetic nephropathy. The company's products in pipeline also comprise INCB28060 and INCB24360, which are Phase II clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Chemistry Biopharmaceutical Chemical Compounds Organic Compounds Solid Tumors Inflammation Psoriasis Pancreatic Cancer Diabetic Nephropathy Janus Kinase Inhibitor Myelofibrosis Clinical Trial Products Nitriles Sulfonamides

Is INCY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 96.79
52 Week Low 62.51
Average Volume 1,882,823
200-Day Moving Average 80.78
50-Day Moving Average 74.53
20-Day Moving Average 70.91
10-Day Moving Average 71.74
Average True Range 4.14
ADX 17.11
+DI 26.23
-DI 16.87
Chandelier Exit (Long, 3 ATRs ) 67.72
Chandelier Exit (Short, 3 ATRs ) 74.94
Upper Bollinger Band 78.31
Lower Bollinger Band 63.51
Percent B (%b) 1.02
BandWidth 20.88
MACD Line 0.00
MACD Signal Line -1.34
MACD Histogram 1.3362
Fundamentals Value
Market Cap 16.17 Billion
Num Shares 206 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -99.48
Price-to-Sales 18.19
Price-to-Book 23.14
PEG Ratio -1.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 81.97
Resistance 3 (R3) 81.89 80.69 81.40
Resistance 2 (R2) 80.69 79.83 80.73 81.21
Resistance 1 (R1) 79.64 79.30 80.17 79.72 81.03
Pivot Point 78.44 78.44 78.70 78.48 78.44
Support 1 (S1) 77.39 77.58 77.92 77.47 76.15
Support 2 (S2) 76.19 77.05 76.23 75.97
Support 3 (S3) 75.14 76.19 75.78
Support 4 (S4) 75.22